PfSPZ Vaccine is a metabolically-active non-replicating whole sporozoite (SPZ) vaccine being developed by Sanaria against Plasmodium falciparum (Pf) malaria. Clinical trials have been safe, extremely well tolerated and highly efficacious. This first generation PfSPZ product is entering phase 3 clinical trials, is attenuated by gamma irradiation and is being closely followed by PfSPZ-CVac and PfSPZ LARC2, that are, respectively, attenuated chemically and genetically. All three products are produced using the same manufacturing process. These products are stored and distributed below -150 °C using liquid nitrogen (LN2) vapor phase (LNVP) freezers and cryoshippers.
Attributes | Values |
---|
rdfs:label
| - PfSPZ vakcína (cs)
- Vaccino PfSPZ (it)
- PfSPZ Vaccine (en)
|
rdfs:comment
| - PfSPZ vakcína je zkušební anti-malarická vakcína připravená z nereplikujících se ozářených s plnou metabolickou aktivitou, která se stále nachází v 1. fázi klinických testů. PfSPZ je zkratkou: Plasmodium falciparum (Pf) (SPZ). (cs)
- PfSPZ Vaccine is a metabolically-active non-replicating whole sporozoite (SPZ) vaccine being developed by Sanaria against Plasmodium falciparum (Pf) malaria. Clinical trials have been safe, extremely well tolerated and highly efficacious. This first generation PfSPZ product is entering phase 3 clinical trials, is attenuated by gamma irradiation and is being closely followed by PfSPZ-CVac and PfSPZ LARC2, that are, respectively, attenuated chemically and genetically. All three products are produced using the same manufacturing process. These products are stored and distributed below -150 °C using liquid nitrogen (LN2) vapor phase (LNVP) freezers and cryoshippers. (en)
- PfSPZ è un candidato vaccino contro la malaria sviluppato da Sanaria ottenuto a partire da sporozoiti non replicanti irradiati. Il nome PfSPZ è composto da due acronimi: Plasmodium falciparium (Pf) e sporozoiti (SPZ). I test clinici condotti finora sono promettenti, ma sono state mosse alcune critiche riguardo alla produzione e alla somministrazione su larga scala del vaccino in Africa, dato che deve essere conservato in azoto liquido (a una temperatura pari o inferiore a -195,79 °C, o 77 K). (it)
|
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
has abstract
| - PfSPZ vakcína je zkušební anti-malarická vakcína připravená z nereplikujících se ozářených s plnou metabolickou aktivitou, která se stále nachází v 1. fázi klinických testů. PfSPZ je zkratkou: Plasmodium falciparum (Pf) (SPZ). (cs)
- PfSPZ Vaccine is a metabolically-active non-replicating whole sporozoite (SPZ) vaccine being developed by Sanaria against Plasmodium falciparum (Pf) malaria. Clinical trials have been safe, extremely well tolerated and highly efficacious. This first generation PfSPZ product is entering phase 3 clinical trials, is attenuated by gamma irradiation and is being closely followed by PfSPZ-CVac and PfSPZ LARC2, that are, respectively, attenuated chemically and genetically. All three products are produced using the same manufacturing process. These products are stored and distributed below -150 °C using liquid nitrogen (LN2) vapor phase (LNVP) freezers and cryoshippers. (en)
- PfSPZ è un candidato vaccino contro la malaria sviluppato da Sanaria ottenuto a partire da sporozoiti non replicanti irradiati. Il nome PfSPZ è composto da due acronimi: Plasmodium falciparium (Pf) e sporozoiti (SPZ). I test clinici condotti finora sono promettenti, ma sono state mosse alcune critiche riguardo alla produzione e alla somministrazione su larga scala del vaccino in Africa, dato che deve essere conservato in azoto liquido (a una temperatura pari o inferiore a -195,79 °C, o 77 K). (it)
|
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
foaf:isPrimaryTopicOf
| |
is rdfs:seeAlso
of | |
is Link from a Wikipage to another Wikipage
of | |
is Wikipage redirect
of | |
is foaf:primaryTopic
of | |